BRCA:
Challenges and Opportunities

May 10 - 13, 2016
Centre Mont-Royal, Montréal, Québec, Canada

Organized by:
Hereditary Breast + Ovarian Cancer Foundation

In collaboration with:
McGill Program in Cancer Genetics, McGill University

www.brcasymposium.ca
Hereditary Breast and Ovarian Cancer Foundation

The Hereditary Breast and Ovarian Cancer Foundation (HBOC) is a community-oriented volunteer driven charity with a tripartite mission: Awareness, Action and Research. It seeks to fulfill its mission by working in cooperation with university or hospital-based programmes in cancer genetics, oncology, surgery, gynecology and plastic and reconstructive surgery. For more information, please visit www.hboc.ca.

Program in Cancer Genetics, McGill University

*Our vision for a comprehensive approach to hereditary cancer.*

Human Genetics is now at the forefront of academic medicine. In addition, its applicability to the management of individuals with, or at risk of, cancer has created the sub-specialty of clinical cancer genetics. Hereditary cancer has been a prominent area of research at McGill University in the last two decades. Our mission is to establish in Montréal a leading multidisciplinary centre for hereditary cancer genetics that will provide an ideal environment for clinical service, research and teaching.

Thank you to our sponsors

The Sixth International Symposium on Hereditary Breast and Ovarian Cancer is grateful for the support of the following organizations:
Who should attend?
Primary care physicians, specialist physicians, laboratory researchers, nurses and genetic counsellors who are interested in furthering their knowledge in the field of hereditary breast and ovarian cancer.

Symposium objectives
The programme was developed to present to both clinicians and researchers the most up-to-date information on hereditary breast and ovarian cancer.

Upon completion of the programme the learner will be able to:
• Better and more efficiently identify individuals who are at high risk for hereditary cancer;
• Review the latest developments in the genetics and molecular science of hereditary breast and ovarian cancer;
• Be able to discriminate between clinically useful and less clinically useful breast cancer susceptibility gene tests;
• Be aware of the science behind the debate concerning the origin of ovarian cancer in BRCA carriers;
• Describe state of the art approaches to the management of individuals with inherited mutations;
• Apply cutting edge science to treat breast and/or ovarian cancer patients who have inherited mutations;
• Identify and understand early diagnostic strategies for individuals at risk for hereditary breast cancer;
• Identify issues and elaborate priorities for hereditary breast and ovarian cancer basic science and clinical research;
• Explain to patients the ethical issues surrounding panel testing for breast and ovarian cancer risk;
• Better understand the factors influencing risk communication among families carrying a BRCA mutation.
Symposium Committees

Organizing Committee

• Chair: Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal
• Scientific Programme Director: William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal
• Public Conference Programme Director: Laura Hayes, McGill University, Montréal

Scientific Programme Committee

• William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal (Chair)
• Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
• Wendy McKinnon, MS, University of Vermont College of Medicine, Burlington, VT, USA
• Jorge Reis-Filho, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
• Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

Abstract Review Committee

• Patricia N. Tonin, PhD, The Research Institute of the MUHC, Montréal, QC, Canada (Chair)
• Ronny Drapkin, MD, PhD, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA
• Lisa Madlensky, PhD, Family Cancer Genetics Program, University of California, San Diego, CA, USA
• Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Study Credit Hours

For this Symposium, we have requested study credits from:

• McGill University, Office for Continuing Health Professional Education which sponsors continuing medical education for physicians. The Office for CHPE McGill University is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME).
• Canadian Association of Genetic Counsellors (CAGC) for “Recognized Educational Session” status eligible for Continuing Education Credits (CECs).
• National Society of Genetic Counselors (NSGC) for Category 1 Continuing Education Units (CEUs) approved by the National Board of Certified Counselors (NBCC) and the American Psychological Association.

Daily sign-in registration will be required in order to receive attestation certificates.

Declaration of Potential Conflict of Interest

Speakers will be requested to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of this programme.
Tuesday, May 10, 2016

16:00 - 21:00 REGISTRATION
19:00 - 21:00 INTRODUCTORY WORKSHOP
Genetics and Genomics Glossary and Get-Together
Genomics nomenclature
Thomas Slavin, MD, FACMG, DABMD, City of Hope, Department of Medical Oncology, Division of Clinical Cancer Genetics, Duarte, CA, USA

Panel testing for breast and ovarian cancer susceptibility – a primer for newbies
Katherine Nathanson, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Basic biology of DNA repair – why the link to breast and ovarian cancer?
Alvaro N. Monteiro, PhD, H. Lee Moffitt Cancer Center & Research Institute, Cancer Epidemiology Program, Division of Population Sciences, Tampa, FL, USA

• Questions and discussion

Wednesday, May 11, 2016

07:00 - 08:00 REGISTRATION & CONTINENTAL BREAKFAST
08:00 - 08:10 Welcome and Introduction to the Programme
Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

08:10 - 08:15 Overview of Today’s Sessions
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada
08:15 - 09:45  **SESSION 1:**
BRCA biology and gene variants

**Chair:** Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

- ClinGen and ClinVar: A new approach to gene variant data  
  Sharon E. Plon, MD, PhD, FACMG, Baylor College of Medicine, Houston, TX, USA
- BRCA1/2 VUS: what’s new in variant classification?  
  Alvaro Monteiro, PhD, H. Lee Moffitt Cancer Center & Research Institute, Cancer Epidemiology Program, Division of Population Sciences, Tampa, FL, USA
- Proffered Papers 1, 2, 3  
- Question and discussion period (all speakers)

09:45 - 10:15 BREAK

10:15 - 11:45  **SESSION 2:**
Implications of DNA defects on the cancer phenotype and management of BRCA mutated cancers

**Chair:** Alvaro Monteiro, PhD, H. Lee Moffitt Cancer Center & Research Institute, Cancer Epidemiology Program, Division of Population Sciences, Tampa, FL, USA

- PolQ and its potential therapeutic implications for BRCA related cancer  
  Agnel Sfeir, PhD, Skirball Institute, New York University, New York, NY, USA
- Pathology of hereditary breast and ovarian cancers, with a focus on those features related to HR DNA repair deficiency  
  Paul van Diest, MD, PhD, Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- Proffered Papers 1, 2, 3  
- Question and discussion period (all speakers)

11:45 - 13:15 LUNCH
13:15 - 14:45 **SESSION 3:**  
BRCA-related ovarian cancer: Origins, diagnosis and outcome  

**Chair:** Ronny Drapkin, MD, PhD, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA

- **Origins of BRCA-related ovarian cancer**  
  Ronny Drapkin, MD, PhD, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA

- **BRCA1/2 germline mutations in acquired resistance and long term survival**  
  David Bowtell, PhD, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia

- **Proffered Papers 1, 2, 3**  
- **Question and discussion period (all speakers)**

14:45 - 16:30 **POSTER SESSION 1 (WITH BREAK)**

16:30 - 18:00 **SESSION 4: SPECIAL DEBATE**  
This house considers that population-based BRCA1/2 testing should be implemented

**Moderator:** Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

**For the motion:**  
Steven Narod, MD, FRCPC, Canada Research Chair in Breast Cancer, Women’s College Research Institute/University of Toronto, Toronto, ON, Canada

**Against the motion:**  
Nicoline Hoogerbrugge, MD, PhD, Radboud University Medical Center, Department of Human Genetics, Nijmegen, The Netherlands
Thursday, May 12, 2016

07:00 - 08:00  CONTINENTAL BREAKFAST

08:00 - 08:15  Introduction to the Day’s Proceedings

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

08:15 - 09:45  SESSION 5: Prevention of HBOC

Chair: Steven Narod, MD, FRCPC, Canada Research Chair in Breast Cancer, Women’s College Research Institute/University of Toronto, Toronto, ON, Canada

- The effect of preventive oophorectomy on breast cancer risk
  Matti Rookus, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands

- Reducing cancer-related mortality in BRCA1/2 mutation carriers
  Steven Narod, MD, FRCPC, Canada Research Chair in Breast Cancer, Women’s College Research Institute/University of Toronto, Toronto, ON, Canada

- Proffered Papers 1, 2, 3
- Question and discussion period (all speakers)

09:45 - 10:15  BREAK

10:15 - 11:45  SESSION 6: Treatment of HBOC

Chair: Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

- Treatment of hereditary breast and ovarian cancer with PARP inhibitors: an update
  Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

- Assessing the role for platinum, taxanes and other chemotherapeutic agents in the treatment of BRCA-related breast cancer
  Andrew Tutt, MB, ChB, PhD, MRCP, FRCR, The Breakthrough Toby Robins Breast Cancer Research Centre, London, UK

- Proffered Papers 1, 2, 3
- Question and discussion period (all speakers)

11:45 - 13:15  LUNCH
13:15 - 14:45 **SESSION 7:**
New challenges in genetic counselling in the era of panel testing

**Chair:** Wendy McKinnon, MS, CGC, Familial Cancer Program, University of Vermont Cancer Center, Burlington, VT, USA

- **Issues facing young women with breast cancer who undergo a panel test**
  Lisa Madlensky, PhD, Family Cancer Genetics Program, University of California, San Diego, CA, USA

- **Genetic counselling models that differ from the standard approach**
  Jill Stopfer, MS, CGC, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

- **Proffered Papers 1, 2, 3**

14:45 - 15:15 **BREAK**

15:15 - 16:45 **SESSION 8:** Special Interest Groups (SIGs)
Moderated interactive discussions with the aim of fostering bilateral knowledge transfer. Participants may attend one of the following concurrent SIGs:
[SEE SECTION ‘E’ ON THE REGISTRATION FORM]

**SIG 1:** Panels: Mutations and VUS: Bring your own cases
Gareth Evans, MB, BS, MD, FRCP, St. Mary’s Hospital, Manchester, UK; Lisa Madlensky, PhD, Family Cancer Genetics Program, University of California, San Diego, CA, USA; Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

**SIG 2:** NGS – beyond the basics and into the nitty gritty
Katherine Nathanson, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Jorge Reis-Filho, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

**SIG 3:** Prostate and Pancreas cancer in high-risk families: Prevention, early diagnosis and treatment
Robert Bristow, PhD, MD, FRCPC, University Health Network-Princess Margaret Hospital, Toronto, ON, Canada; George Zogopoulos, MD, PhD, McGill University, Montréal, QC, Canada

**SIG 4:** Next-generation genetic counselling: Effective tools for promoting risk management adherence & psychosocial adjustment
Karen Hurley, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Wendy McKinnon, MS, CGC, Familial Cancer Program, University of Vermont Cancer Center, Burlington, VT, USA

16:45 - 18:30 **POSTER SESSION 2**
Friday, May 13, 2016

07:00 - 08:00 CONTINENTAL BREAKFAST
08:00 - 08:15 Introduction to the Day's Proceedings
Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada
William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

08:15 - 09:45 SESSION 9: Panels for HBOC – The way forward
Chair: Paul Pharaoh, BM, BCh, PhD, University of Cambridge, Cambridge, UK
- Cancer susceptibility gene panels: Basic principles
  Paul Pharaoh, BM, BCh, PhD, University of Cambridge, Cambridge, UK
- Breast and ovarian cancer susceptibility genes: Which genes are ready to be included in panels?
  Douglas Easton, PhD, University of Cambridge, Cambridge, UK
- Proffered Papers 1, 2, 3
- Question and discussion period (all speakers)

09:45 - 10:15 BREAK

10:15 - 11:45 SESSION 10: New genes, old genes and modifiers
Chair: Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK
- Variants that modify breast and ovarian cancer risk in BRCA1/2 carriers: The CIMBA experience
  Georgia Chenevix-Trench, PhD, Head, Cancer Genetics Laboratory, QIMR Berghofer, Brisbane, QLD, Australia
- The inherited contribution to triple negative breast cancer: BRCA1, BRCA2 and beyond
  Fergus Couch, PhD, Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
- Proffered Papers 1, 2, 3
- Question and discussion period (all speakers)
11:55 - 13:10  **CLOSING SESSION:**  
The Marla Miller Memorial Lecture  

- **Introductory Remarks**  
  **William Foulkes**, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada  

- **Hereditary breast and ovarian cancer in the era of precision medicine**  
  **Francis Collins**, MD, PhD, Director, National Institutes of Health, Bethesda, MD, USA  

- **Presentation by the Miller Family**  

- **Closing Remarks**  
  **Harley Eisman**, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada  

---  

**Marla Miller-Gross**  

Marla Miller-Gross passed away less than two years after being diagnosed with "routine" breast cancer, months shy of her fortieth birthday. Marla's courage in opting for genetic testing has touched lives far far beyond those that she befriended while living.  

*Out of Marla's tragedy, HBOC was born and the drive to improve the outcome of women and families with hereditary breast and ovarian cancer.*
Call for Abstracts

Building on the success of the last Symposium, the Programme Committee is pleased to once again issue a Call for Abstracts for oral and poster presentations.

Interested participants are invited to submit abstracts on topics related to hereditary breast and ovarian cancer. Submissions are welcome from all disciplines. Specific topic categories are listed below. Abstracts may be in English or French.

Abstracts accepted for presentation as orals will be included in the programme as 10-minute proffered papers. Presenters will take part with the invited faculty in the question and discussion period scheduled in each session.

Deadline for Oral Abstract Submissions: November 30, 2015
Deadline for Poster Abstract Submissions: January 22, 2016

Publication of Abstracts
All accepted abstracts will be published in the Symposium Book of Abstracts.

How to Submit an Abstract
Please complete the Online Abstract Submission Form on the Symposium website: www.brcasymposium.ca

Topic Categories
- BRCA1/2 mutations, variants of unknown clinical significance and databases
- Molecular pathology and genetic analyses of BRCA1/2-associated cancers
- Biology of hereditary cancers
- Non-BRCA1/2 genetic factors associated with cancer risk
- Genome-wide approaches aimed at identifying new genetic risk factors
- Risk assessment and genetic counselling issues
- Clinical issues for management
- Psycho-oncology
- Education
- Ethics and legal issues
Full-Day Conference for the General Public

Living with BRCA:
4th Biennial Conference on Hereditary Breast and Ovarian Cancer for Gene-Carriers, At-Risk Individuals, and Their Families

Wednesday, May 11, 2016, 8:10 – 16:30
Centre Mont-Royal, Montréal, Québec

A one day conference for the general public that provides up-to-date clinical and research information focused on hereditary breast and ovarian cancer. This event brings together experts in medicine, biology, psychology, and wellness, all of whom are united in one goal: bettering the lives of those living with BRCA and their families and friends.

Attendees will have the opportunity to learn about:
• The most current information about cancer risks, surveillance, and risk reduction options for BRCA1 and BRCA2 carriers;
• The latest in HBOC research;
• Surgical approaches to mastectomy & breast reconstruction;
• Body image and sexuality after risk-reducing surgery or cancer;
• Genetics of HBOC: BRCA and beyond;
• The experiences of others living with BRCA, including patient testimonials.

Please assist us by inviting your patients, friends, and colleagues who may be interested in learning more about the impact of living with BRCA1/2.

ORGANIZING COMMITTEE
Laura Hayes, McGill University, Montréal, QC, Canada (Chair)
Nadine Dumas, MSc, CCGC, Service de médecine génique, CHUM, Montréal, QC, Canada
Laura Palma, MSc, CCGC, CGC, McGill University Health Centre, Montréal, QC, Canada
Nora Wong, MS, CCGC, Jewish General Hospital, Montréal, QC, Canada
Registration Information

How to Register
You may register online at www.brcasymposium.ca or complete the registration form on pages 15-16 and mail or fax it to the Symposium Secretariat.

Cancellation Policy
Full refunds, less an administrative fee of $50.00, will be made for written cancellations received by February 21, 2016. After February 21, 2016, only 50% will be refunded, and no refunds will be issued for cancellations received after March 18, 2016.

Symposium Secretariat
BRCA Symposium Secretariat
c/o O’Donoughue & Associates Event Management Ltd.
75 chemin Mountain
Mansonville, QC
Canada J0E 1X0
Telephone: +1 450-292-3456, ext. 227
Fax: +1 450-292-3453
Email: registration@brcasymposium.ca

Symposium Venue
Centre Mont-Royal
2200 Mansfield Street,
Montréal, QC, Canada

Hotel Accommodation
Take advantage of the great hotel rates that have been negotiated!

HOTEL OMNI MONT-ROYAL
1050 Sherbrooke Street West
Tel: +1 514-284-1110
Toll-free: 1-800-843-6664*
Rate: $189 CAD per night
single or double occupancy
(Valid only until April 11, 2016)

LE ST-MARTIN HÔTEL PARTICULIER – CENTRE-VILLE
980 de Maisonneuve West
Tel: +1 514-843-3000
Toll-free: 1-877-843-3003*
Rate: $179 CAD per night
single or double occupancy
(Valid only until April 10, 2016)

BEST WESTERN VILLE-MARIE HOTEL & SUITES
3407 Peel Street
Tel: +1 514-288-4141
Toll-free: 1-800-361-7791*
Rate: $159 CAD per night
single or double occupancy
(1 Queen bed)
$169 CAD per night
single or double occupancy
(2 Queen beds)
(Valid only until March 31, 2016)

Rates do not include the 3.5% lodging tax, nor the applicable taxes (GST: 5% and QST: 9.975%) per room, per night.
*Toll-free numbers are for Canada & USA only.

If you wish to make your reservation online, please visit our “Accommodation” page at www.brcasymposium.ca. Remember to mention that you are participating in the Hereditary Breast and Ovarian Cancer (HBOC) Symposium to receive the preferential room rates.
Registration Form
BRCA: Challenges and Opportunities
May 10-13, 2016
Centre Mont-Royal, 2200 Mansfield Street, Montréal

Please fax or mail your completed form, along with your payment, to:

BRCA Symposium Secretariat
c/o O’Donoughue & Associates Event Management Ltd.
75 chemin Mountain, Mansonville, Québec, Canada J0E 1X0
Tel: +1 450-292-3456, ext. 227 • Fax: +1 450-292-3453
Email: registration@brcasymposium.ca • Web site: www.brcasymposium.ca

Please use one form per registrant

A. Identification (Please type or print legibly)

Prefix (Please circle one): Prof. • Dr. • Mr. • Ms • Mrs. • Other...............................

Last Name.....................................................................First Name.................................................................

Title/Position..............................................................................................................................................

Department/Division.................................................................................................................................

Organization..............................................................................................................................................

Address........................................................................................................................................................

City...........................................................................Province / State..............................................................

Country..............................................................................Postal / Zip Code......................................................

Telephone (...........)........................................Fax (...........)...........................................................

Email...........................................................................................................................................................

☐ Resident    ☐ MD    ☐ Nurse    ☐ Genetic Counsellor    ☐ Other........................................

Medical Specialty: .........................................................MD (in year)....................

☐ Please check here if you do not want your email address to appear on the list of participants which may be distributed to participants.

B. Special Needs

Please indicate any special needs you may have (e.g. dietary, wheelchair access, etc.)

........................................................................................................................................................................
........................................................................................................................................................................

Please complete both sides of this form.
Registration Form (cont’d)

C. Symposium Registration Please check one only:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician, Pharmacist</td>
<td>☐ $660</td>
<td>☐ $775</td>
<td>☐ $925</td>
<td>$</td>
</tr>
<tr>
<td>Genetic Counsellor / Nurse</td>
<td>☐ $505</td>
<td>☐ $595</td>
<td>☐ $715</td>
<td>$</td>
</tr>
<tr>
<td>Post Doc./ Resident¹</td>
<td>☐ $480</td>
<td>☐ $570</td>
<td>☐ $680</td>
<td>$</td>
</tr>
<tr>
<td>Student²</td>
<td>☐ $360</td>
<td>☐ $420</td>
<td>☐ $505</td>
<td>$</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician, Pharmacist</td>
<td>☐ $390</td>
<td>☐ $415</td>
<td>☐ $450</td>
<td>$</td>
</tr>
<tr>
<td>Genetic Counsellor / Nurse</td>
<td>☐ $290</td>
<td>☐ $315</td>
<td>☐ $345</td>
<td>$</td>
</tr>
<tr>
<td>Post Doc./ Resident¹</td>
<td>☐ $280</td>
<td>☐ $315</td>
<td>☐ $345</td>
<td>$</td>
</tr>
<tr>
<td>Student²</td>
<td>☐ $210</td>
<td>☐ $230</td>
<td>☐ $250</td>
<td>$</td>
</tr>
<tr>
<td>Introductory Workshop</td>
<td>☐ $50</td>
<td>☐ $55</td>
<td>☐ $60</td>
<td>$</td>
</tr>
</tbody>
</table>

☐ Tuesday ☐ Wednesday ☐ Thursday ☐ Friday

TOTAL REGISTRATION FEES: $

The Full Symposium registration fees include access to sessions, continental breakfast each day, buffet lunch (May 11-12), coffee breaks, and the Symposium documentation.

¹ Please provide proof of Post Doc / Resident status, i.e. letter from your programme director.
² Please provide proof of full-time student status, i.e. copy of current student card or letter from your programme director.

D. Method of Payment (in Canadian funds)

Paying by: ☐ Cheque (payable to O’Donoughue & Associates Event Management re: BRCA)
☐ MasterCard ☐ VISA ☐ AMEX

Credit Card # .................................................................................................................. Expiry Date

Name on Credit Card .................................................................................................................

I hereby authorize O’Donoughue & Associates Event Management Ltd. to debit my credit card for the amount indicated above in “TOTAL REGISTRATION FEES” and I acknowledge having read the cancellation policy on page 14.

Signature of cardholder ........................................................................................................... Date

E. Special Interest Group (SIG) Preferences (Thursday, May 12, 2016)

Please rank the SIGs in order of your preference (1-4).
You will be assigned to one SIG on a first come-first served basis.

☐ Panels: Mutations and VUS: Bring your own cases
☐ NGS – beyond the basics and into the nitty gritty
☐ Prostate and Pancreas cancer in high-risk families – Prevention, early diagnosis and treatment
☐ Next-generation genetic counseling: Effective tools for promoting risk management adherence & psychosocial adjustment

Please complete both sides of this form.